Potential Solutions to Disparities in Stem Cell Transplant for Blood Cancer

Commentary
Video

Resolving disparities within the blood cancer space is a matter of “access to excellent healthcare,” according to Usama Gergis, MD, MBA.

In a conversation with CancerNetwork®, Usama Gergis, MD, MBA, suggested that accessibility to high quality healthcare is a key factor in overcoming disparities in receipt of step cell transplant for patients with hematologic malignancies.

In particular, he cited distance to treatment centers as one of the contributing challenges, noting that there are patients who drive up to 3 hours to receive treatment at his institution. However, Gergis, the director of Stem Cell Transplant and Cellular Therapy Program at Jefferson Health, noted that his institution is in the process of setting up several satellite transplant clinics that will allow patients to receive their pre-transplant and post-transplant care. Reducing the distance traveled may help in making the stem cell transplant process more feasible for this population, many of whom are elderly.

Transcript:

There is a global solution to disparities in health care, whether that is allogeneic transplant or triple bypass [surgery]. There is a specific transplant goal. I would think that access to excellent health care will address this disparity right at the core. For example, our catchment area here in Center City, Philadelphia is huge. When I was in Cornell in New York, I thought it was larger for people coming from Long Island, Westchester, Brooklyn, or Queens. But looking at the geographic location of our patients here, there are people coming from 2 or 3 hours [away] who are driving to Center City.

For someone with blood cancer who might require close monitoring twice a week, and with the understanding that blood cancer is a disease of older age—for acute myeloid leukemia, the median age is 68 years—children and grandchildren will need to [accompany their grandparents] to Center City. As a way of addressing this, we are setting up satellite transplant clinics closer to home. We do not have to do transplant at [any one location]. We don't have to do that. But allogeneic transplant is a lifelong [treatment].

We [decided] to do transplant here in Center City, but we will do the pre- and post-transplant [treatment] closer to home. The driving distance to a transplant center has shown potential to be a barrier to cellular therapy.

Related Videos
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
D. Ross Camidge, MD, PhD, spoke about how the approval of alectinib is the beginning of multiple other approvals for patients with ALK-positive NSCLC.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
The use of proton therapy may offer a more specific depth charge compared with conventional radiation, according to Timothy Chen, MD.
Related Content